Top

Published in:

01-08-2020 | Chloroquin | Perspectives in Rheumatology

Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?

Authors: Sebastián Ibáñez, Oriela Martínez, Francisca Valenzuela, Francisco Silva, Omar Valenzuela

Published in: Clinical Rheumatology | Issue 8/2020

Abstract

The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19.

Devaux CA, Rolain J-M, Colson P, Raoult D (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 105938:105938. https://doi.org/10.1016/j.ijantimicag.2020.105938CrossRef

Schrezenmeier E, Dörner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16:155–166. https://doi.org/10.1038/s41584-020-0372-xCrossRefPubMed

Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:72–73. https://doi.org/10.5582/bst.2020.01047CrossRefPubMed

Kwiek JJ, Haystead TAJ, Rudolph J (2004) Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry 43:4538–4547. https://doi.org/10.1021/bi035923wCrossRefPubMed

Olofsson S, Kumlin U, Dimock K, Arnberg N (2005) Avian influenza and sialic acid receptors: more than meets the eye? Lancet Infect Dis 5:184–188. https://doi.org/10.1016/S1473-3099(05)01311-3CrossRefPubMed

Zeng Q, Langereis MA, van Vliet ALW, Huizinga EG, de Groot RJ (2008) Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci U S A 105:9065–9069. https://doi.org/10.1073/pnas.0800502105CrossRefPubMedPubMedCentral

Bakkers MJG, Lang Y, Feitsma LJ, Hulswit RJG, de Poot SAH, van Vliet ALW, Margine I, de Groot-Mijnes JDF, van Kuppeveld FJM, Langereis MA, Huizinga EG, de Groot RJ (2017) Betacoronavirus adaptation to humans involved progressive loss of hemagglutinin-esterase lectin activity. Cell Host Microbe 21:356–366. https://doi.org/10.1016/j.chom.2017.02.008CrossRefPubMedPubMedCentral

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2:69. https://doi.org/10.1186/1743-422X-2-69CrossRefPubMedPubMedCentral

Yang Z-Y, Huang Y, Ganesh L, Leung K, Kong WP, Schwartz O, Subbarao K, Nabel GJ (2004) pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 78:5642–5650. https://doi.org/10.1128/JVI.78.11.5642-5650.2004CrossRefPubMedPubMedCentral

10.

Tricou V, Minh NN, Van TP et al (2010) A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 4. https://doi.org/10.1371/journal.pntd.0000785

11.

Gay B, Bernard E, Solignat M, Chazal N, Devaux C, Briant L (2012) pH-dependent entry of chikungunya virus into Aedes albopictus cells. Infect Genet Evol 12:1275–1281. https://doi.org/10.1016/j.meegid.2012.02.003CrossRefPubMed

12.

Khan M, Santhosh SR, Tiwari M, Lakshmana Rao PV, Parida M (2010) Assessment of in vitro prophylactic and therapeutic efficacy of chloroquine against chikungunya virus in vero cells. J Med Virol 82:817–824. https://doi.org/10.1002/jmv.21663CrossRefPubMedPubMedCentral

13.

Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C (2008) SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 18:290–301. https://doi.org/10.1038/cr.2008.15CrossRefPubMed

14.

Simmons G, Bertram S, Glowacka I, Steffen I, Chaipan C, Agudelo J, Lu K, Rennekamp AJ, Hofmann H, Bates P, Pöhlmann S (2011) Different host cell proteases activate the SARS-coronavirus spike-protein for cell–cell and virus–cell fusion. Virology 413:265–274. https://doi.org/10.1016/j.virol.2011.02.020CrossRefPubMed

15.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30:269–271. https://doi.org/10.1038/s41422-020-0282-0CrossRefPubMedPubMedCentral

16.

Seitz M, Valbracht J, Quach J, Lotz M (2003) Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. J Clin Immunol 23:477–484. https://doi.org/10.1023/B:JOCI.0000010424.41475.17CrossRefPubMed

17.

Briant L, Robert-Hebmann V, Acquaviva C et al (1998) The protein tyrosine kinase p56 lck is required for triggering NF-κB activation upon interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with cell surface CD4. J Virol 72:6207–6214CrossRefPubMedPubMedCentral

18.

Kono M, Tatsumi K, Imai AM, Saito K, Kuriyama T, Shirasawa H (2008) Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antivir Res 77:150–152. https://doi.org/10.1016/j.antiviral.2007.10.011CrossRefPubMed

19.

Accapezzato D, Visco V, Francavilla V, Molette C, Donato T, Paroli M, Mondelli MU, Doria M, Torrisi MR, Barnaba V (2005) Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo. J Exp Med 202:817–828. https://doi.org/10.1084/jem.20051106CrossRefPubMedPubMedCentral

20.

Garulli B, Di Mario G, Sciaraffia E et al (2013) Enhancement of T cell-mediated immune responses to whole inactivated influenza virus by chloroquine treatment in vivo. Vaccine 31:1717–1724. https://doi.org/10.1016/j.vaccine.2013.01.037CrossRefPubMed

21.

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R (2003) Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis 3:722–727. https://doi.org/10.1016/S1473-3099(03)00806-5CrossRefPubMedPubMedCentral

22.

Jang C-H, Choi J-H, Byun M-S, Jue D-M (2006) Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology 45:703–710. https://doi.org/10.1093/rheumatology/kei282CrossRefPubMed

23.

Picot S, Peyron F, Donadille A, Vuillez JP, Barbe G, Ambroise-Thomas P (1993) Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 80:127–133PubMedPubMedCentral

24.

Jeong JY, Jue DM (1997) Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 158:4901–4907PubMed

25.

Zhu X, Ertel W, Ayala A et al (1993) Chloroquine inhibits macrophage tumour necrosis factor-alpha mRNA transcription. Immunology 80:122–126PubMedPubMedCentral

26.

Weber SM, Levitz SM (2000) Chloroquine interferes with lipopolysaccharide-induced TNF-α gene expression by a nonlysosomotropic mechanism. J Immunol 165:1534–1540. https://doi.org/10.4049/jimmunol.165.3.1534CrossRefPubMed

27.

Randolph VB, Winkler G, Stollar V (1990) Acidotropic amines inhibit proteolytic processing of flavivirus prM protein. Virology 174:450–458. https://doi.org/10.1016/0042-6822(90)90099-DCrossRefPubMed

28.

Sahraei Z, Shabani M, Shokouhi S, Saffaei A (2020) Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents 105945:105945. https://doi.org/10.1016/j.ijantimicag.2020.105945CrossRef

29.

Rynes RI, Bernstein HN (1993) Ophthalmologic Safety Profile of Antimalarial Drugs. https://journals.sagepub.com/doi/abs/10.1177/0961203393002001051. Accessed 26 Apr 2020

30.

Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, Wang M (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6:1–4. https://doi.org/10.1038/s41421-020-0156-0CrossRefPubMedPubMedCentral

31.

multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia (2020) Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi Zhonghua Jiehe He Huxi Zazhi Chin J Tuberc Respir Dis 43:185–188. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.03.009CrossRef

32.

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial | medRxiv. https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2. Accessed 7 Apr 2020

33.

Chinese Clinical Trial Register (ChiCTR) (2020) The world health organization international clinical trials registered organization registered platform. https://web.archive.org/web/20200331075326/http://webcache.googleusercontent.com/search?q=cache:-SdEu1yXCaAJ:www.chictr.org.cn/showprojen.aspx%3Fproj%3D48880+&cd=1&hl=en&ct=clnk&gl=de&client=firefox-b-d. Accessed 19 Apr 2020

34.

Jun C, Jun C (2020) A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci) 49:0–0. https://doi.org/10.3785/j.issn.1008-9292.2020.03.03

35.

Gautret P, Lagier J-C, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

36.

Hulme OJ, Wagenmakers E-J, Damkier P et al (2020) Reply to Gautret et al. 2020: a Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19 medRxiv 2020.03.31.20048777. https://doi.org/10.1101/2020.03.31.20048777

37.

Groupe Veille Coronavirus GVC (2020) Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study. https://www.groupedeveillecovid.fr/blog/2020/03/28/clinical-and-microbiological-effect-of-a-combination-of-hydroxychloroquine-and-azithromycin-in-80-covid-19-patients-with-at-least-a-six-day-follow-up-an-observational-study/. Accessed 7 Apr 2020

38.

Molina JM, Delaugerre C, Goff JL et al (2020) No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 50:384. https://doi.org/10.1016/j.medmal.2020.03.006CrossRefPubMedPubMedCentral

39.

Tang W, Cao Z, Han M, et al (2020) Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial. medRxiv 2020.04.10.20060558. https://doi.org/10.1101/2020.04.10.20060558

40.

Mahevas M, Tran V-T, Roumier M, et al (2020) No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv 2020.04.10.20060699. https://doi.org/10.1101/2020.04.10.20060699

41.

Chorin E, Dai M, Shulman E, et al (2020) The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. medRxiv 2020.04.02.20047050. https://doi.org/10.1101/2020.04.02.20047050

42.

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study | medRxiv. https://www.medrxiv.org/content/10.1101/2020.04.08.20054551v1. Accessed 20 Apr 2020

43.

Borba MGS, Val F de A, Sampaio VS, et al (2020) Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). medRxiv 2020.04.07.20056424. https://doi.org/10.1101/2020.04.07.20056424

Title: Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
Authors: Sebastián Ibáñez
Oriela Martínez
Francisca Valenzuela
Francisco Silva
Omar Valenzuela
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Chloroquin
Azithromycin
Antimalaria
Chloroquin
SARS-CoV-2
COVID-19
Hydroxychloroquine
Published in: Clinical Rheumatology / Issue 8/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05202-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2020

The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort

Impact of anti-rheumatic drugs and steroids on clinical course and prognosis of COVID-19

Spondyloarthritis is associated with higher healthcare utilization and complication rates after primary total knee or total hip arthroplasty

MTHFR gene polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis based on 16 studies

Spotted bone disease

Impact of Ramadan diurnal intermittent fasting on rheumatic diseases

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials